Kura Oncology, Inc. (KURA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Kura Oncology, Inc. (KURA)
Go deeper and ask any question about KURA
Company Performance
Current Price
as of Sep 13, 2024$20.88
P/E Ratio
N/A
Market Cap
$1.6B
Description
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Metrics
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerKURA
- Price$20.88+4.98%
Trading Information
- Market Cap$1.60B
- Float84.72%
- Average Daily Volume (1m)389,026
- Average Daily Volume (3m)677,874
- EPS-$2.23
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$50.84M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$56.20M
- EV$1.31B
- EV/RevenueN/A
- P/EN/A
- P/SN/A